Results 71 to 80 of about 319,380 (216)

Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey

JID Innovations
The National Psoriasis Foundation surveyed a random, stratified sample of individuals with psoriatic disease in the United States to determine the prevalence of an unacceptable psoriatic arthritis (PsA) symptom state and its effect on depression and ...
Melissa P. Zundell, Alexis R. Ogdie-Beatty, Lourdes Perez-Chada, Hassan Hamade, George C. Gondo, Ali T. Khan, Stacie J. Bell, Zachary Levy, Joseph F. Merola, Alice B. Gottlieb   +9 more
doaj   +1 more source

Quality of life and psycho-emotional status of patients with psoriatic arthritis

Научно-практическая ревматология, 2009
Quality of life and psycho-emotional status of patients with psoriatic arthritis. Objective. To assess quality of life (QL) and psycho-emotional status of patients with psoriatic arthritis (PsA). Material and methods.
O G Filimonova, O V Simonova
doaj   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis

Clinical, Cosmetic and Investigational Dermatology, 2010
Melissa A Michelon1, Alice B Gottlieb1,21Tufts University School of Medicine, 2Department of Dermatology, Tufts Medical Center, Boston, MA, USAAbstract: Psoriatic arthritis (PsA) is an inflammatory arthritis that affects many psoriasis patients and can ...
Melissa A Michelon, Alice B Gottlieb
doaj  

Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease

Advances in Rheumatology, 2020
Background Psoriatic arthritis (PsA) is a chronic inflammatory disease of widely varying presentation, which determines functional and psychological impairment, with a high negative impact on patients’ quality of life.
Elziane da Cruz Ribeiro e Souza, Sueli Coelho da Silva Carneiro, Michel Alexandre Yazbek, Rita de Cássia Menin, Cristiano Barbosa Campanholo, Jamille Nascimento Carneiro, Carlos Henrique Martis da Silva, Roberto Ranza   +7 more
doaj   +1 more source

Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. [PDF]

PLoS ONE, 2011
This study correlated assessment tools for evaluating the severity of skin, nail, and joint symptoms in patients with psoriasis (Pso) and psoriatic arthritis (PsA). Adults with plaque Pso (with or without PsA) were enrolled from four U.S.
Knut M Wittkowski, Craig Leonardi, Alice Gottlieb, Alan Menter, Gerald G Krueger, Paul W Tebbey, Jennifer Belasco, Razieh Soltani-Arabshahi, John Gray, Liz Horn, James G Krueger, International Psoriasis Council   +11 more
doaj   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

The role of the gut microbiome in psoriatic arthritis pathophysiology, a phenomic study

, 2023
: Background: Psoriasis is a chronic inflammatory disease of the skin affecting 2-3% of UK population. 30% of people affected by psoriasis will develop a progressive form of arthritis within 10 years of the skin condition onset. Psoriatic arthritis (PsA,
Miguens Blanco, Jesus
core   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Certolizumab pegol – new option in the treatment of psoriatic arthritis [PDF]

, 2014
It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis.
Anna Siwiec, Maria Majdan, Aleksandra Gryta   +2 more
core   +1 more source